Identification of Distinct Subgroups in Moderately Severe Rheumatic Mitral Stenosis Using Data-Driven Phenotyping of Longitudinal Hemodynamic Progression.
Kyu‐Yong Ko,Iksung Cho,Subin Kim,Yeonchan Seong,Dae‐Young Kim,Ji Won Seo,Seng Chan You,Chi Young Shim,Geu‐Ru Hong,Jong‐Won Ha
DOI: https://doi.org/10.1161/JAHA.121.026375
IF: 6.106
2022-07-30
Journal of the American Heart Association
Abstract:Background Rheumatic mitral stenosis is a significant cause of valvular heart disease. Pulmonary arterial systolic pressure (PASP) reflects the hemodynamic consequences of mitral stenosis and is used to determine treatment strategies. However, PASP progression and expected outcomes based on PASP changes in patients with moderately severe mitral stenosis remain unclear. Methods and Results A total of 436 patients with moderately severe rheumatic mitral stenosis (valve area 1.0–1.5 cm 2 ) were enrolled. Composite outcomes included all‐cause mortality and hospitalization for heart failure. Data‐driven phenotyping identified 2 distinct trajectory groups based on PASP progression: rapid (8.7%) and slow (91.3%). Patients in the rapid progression group were older and had more diabetes and atrial fibrillation than those in the slow progression group (all P <0.05). The initial mean diastolic pressure gradient and PASP were higher in the rapid progression group than in the slow progression group (6.2±2.4 mm Hg versus 5.1±2.0 mm Hg [ P =0.001] and 42.3±13.3 mm Hg versus 33.0±9.2 mm Hg [ P <0.001], respectively). The rapid progression group had a poorer event‐free survival rate than the slow progression group (log‐rank P <0.001). Rapid PASP progression was a significant risk factor for composite outcomes even after adjusting for comorbidities (hazard ratio, 3.08 [95% CI, 1.68–5.64]; P 40 mm Hg was independently associated with allocation to the rapid progression group (odds ratio, 4.95 [95% CI, 2.08–11.99]; P <0.001). Conclusions Rapid PASP progression was associated with a higher risk of the composite outcomes. The main independent predictor for rapid progression group allocation was initial PASP >40 mm Hg. Nonstandard Abbreviations and Acronyms LCTM latent class trajectory modeling MV mitral valve MVA mitral valve area MVR mitral valve replacement PASP pulmonary arterial systolic pressure PBMC percutaneous balloon mitral commissurotomy TTE transthoracic echocardiography Clinical Perspective What Is New? This study leveraged a longitudinal value to evaluate the long‐term trajectories of hemodynamic progression in patients with moderately severe rheumatic mitral stenosis. Two distinct trajectories were identified according to the progression of pulmonary arterial systolic pressure (PASP). The rapid progression of PASP was a significant prognostic factor for poorer clinical outcomes during a 10‐year follow‐up, and initial PASP >40 mm Hg was an independent determining factor for rapid progression group allocation. What Are the Clinical Implications? Careful clinical attention, including more frequent follow‐up, is warranted for patients with rapid PASP progression. These results imply that patients with PASP >40 mm Hg, atrial fibrillation, and diabetes may require closer follow‐up with increased surveillance with echocardiography because of the risk of a rapid increase in PASP. Rheumatic heart disease is a significant global health issue, with 282 000 new cases occurring annually. 1 At least 15.6 million people are estimated to be living with rheumatic heart disease worldwide, and the prevalence of heart failure (HF) attributable to rheumatic heart disease increased by 88% from 1990 to 2015. 1 , 2 The mitral valve (MV) is the valve most frequently affected by rheumatic fever, and mitral stenosis (MS) develops as a result of repeated or persistent valvulitis. 3 , 4 Current guidelines define severe or significant MS as MV area (MVA) <1.5 cm. 5 , 6 However, previous studies investigating MS prognosis have commonly targeted patients with MVA ≤1.0 cm 2 based on prior guidelines. 7 , 9 Th -Abstract Truncated-
cardiac & cardiovascular systems